MIGRATION OF DENDRITIC LEUKOCYTES
FROM CARDIAC ALLOGRAFTS INTO HOST
SPLEENS - A NOVEL PATHWAY FOR
INITIATION OF REJECTION

Christian Larsen, Emory University
CP LARSEN
PJ MORRIS
JM AUSTYN

Journal Title: Journal of Experimental Medicine
Volume: Volume 171, Number 1
Publisher: ROCKEFELLER UNIV PRESS | 1990-01-01, Pages 307-314
Type of Work: Article
Publisher DOI: 10.1084/jem.171.1.307
Permanent URL: https://pid.emory.edu/ark:/25593/vgpwg

Final published version: http://dx.doi.org/10.1084/jem.171.1.307
Accessed August 30, 2020 2:23 AM EDT
MIGRATION OF DENDRITIC LEUKOCYTES FROM CARDIAC ALLOGRAFTS INTO HOST SPLEENS
A Novel Pathway for Initiation of Rejection

By CHRISTIAN P. LARSEN, PETER J. MORRIS, AND JONATHAN M. AUSTYN

From The Nuffield Department of Surgery, University of Oxford, John Radcliffe Hospital, Headington, Oxford OX3 9DU, United Kingdom

Dendritic leukocytes (DL) from lymphoid tissues are specialized antigen-presenting cells that initiate immune responses (1). There is evidence that related cells in transplanted tissues (passenger leukocytes) are the principal stimulators of rejection but it is not known where they initially activate host T cells (2). The prevailing view is that for fully vascularized organ allografts sensitization occurs within the graft itself (i.e., peripherally) (3–5), while for skin grafts it occurs in the draining lymph nodes (i.e., centrally) (6–8). In this report we show that donor-derived MHC class II-positive (Ia+) DL migrate rapidly out of mouse cardiac allografts into the recipients’ spleens where they home to the peripheral white pulp and associate predominantly with CD4+ T lymphocytes. This provides a novel route for central sensitization against fully vascularized allografts, and most likely represents a pathway by which immune responses are generated against antigens on blood-borne DL emigrating from peripheral tissues.

While dendritic cells (DC) isolated from lymphoid tissues, lymph, and blood can initiate immune responses, their precursors in skin, Langerhans cells (LC), lack this ability. LC, however, can mature into potent stimulatory cells (9) and migrate as veiled cells via the lymph into lymph nodes (10, 11); by a second route purified lymphoid DC that are administered intravenously can migrate from blood into spleen and home to T areas (12, 13). Bone marrow–derived Ia+ cells with dendritic morphology have been identified in a wide variety of nonlymphoid organs and are presumed to be DL (14). Recent work suggests these cells in kidney, heart, and perhaps other nonlymphoid organs are immature precursors more closely resembling LC than lymphoid DC (Austyn, J., and C. Larsen, unpublished data).

This work was supported by the Medical Research Council and the National Kidney Research Fund of the United Kingdom. C. P. Larsen is a Livingston Surgical Research Fellow (Emory University and Piedmont Hospital, Atlanta, GA) and the recipient of a Henry Goodger Scholarship (University of Oxford) and a British-American Research Fellowship from the American Heart Association and the British Heart Foundation.

Address correspondence to Dr. Jonathan Austyn, The Nuffield Department of Surgery, University of Oxford, John Radcliffe Hospital, Headington, Oxford OX3 9DU, United Kingdom.

1 Abbreviations used in this paper: DC, lymphoid dendritic cells; DL, dendritic leukocytes; LC, Langerhans cells.
Materials and Methods

Mice
Male C57BL/10 (H-2b), BALB/c (H-2d), CBA/Ca (H-2k), and C3H/He (H-2'), mice were obtained from Olac Ltd. (Bicester, Oxon, UK) or from the Biomedical Services Unit, John Radcliffe Hospital, University of Oxford.

Cardiac Transplantation
BALB/c hearts were transplanted as fully vascularized, heterotopic grafts into C3H/He recipients essentially as described (15). Technical success was >95% and the total ischemic time was generally 20–25 min. The amount of donor blood transferred to recipients in the grafts was minimized by removing ~0.7 ml blood from the vena cava, injecting 1 ml heparinized saline (300 U/ml) at 4°C, and allowing this to circulate before severing the abdominal aorta and vena cava. Donor hearts were then dissected out and gently massaged between cotton buds in saline at 4°C.

Measurement of the Volume of Blood Contained in a Transplanted Heart
The average volume of blood contained within a graft was determined using 51Cr-labeled mouse erythrocytes essentially as described (16): cells containing 150,000 cpm in 0.25 ml PBS were injected intravenously into three mice and after 20–30 min a sample of peripheral blood was taken and the heart was prepared as for transplantation (Table I).

Immunohistology
Monoclonal Antibodies. The following mAbs were used as tissue culture supernatants for first stage antibodies: TIB122 anti-leukocyte common antigen, 24G2 anti-Fc receptor type II, M70 (TIB 128) anti-C3bi receptor, GKL5 anti-CD4, TIB 105 anti-CD8, TIB 104 anti-CD5, TIB 145 anti-B220, TIB 146 anti-B p50, 2D2C anti-Pgp-1.1 (Ly24), B21-2 (TIB 229) anti-Ia6, all of which are rat monoclonals, and MKD6 anti-Ia which is a mouse mAb (antibodies in reference 17). For two-color staining biotinylated YTS 191, rat IgG2b anti-CD4 and YTS 169, and rat IgG2b anti-CD8 were used (18; both kind gifts from K. Wood, Nuffield Dept. of Surgery).

Tissue Preparation. Multiple cryosections (7 µm) of heart and spleen from transplanted and normal mice embedded in OCT compound (Miles Scientific) were prepared and stored at ~30°C until use. For staining, the sections were fixed in acetone for 10 min, air dried and rehydrated in PBS with 1% fetal calf serum.

Two-Color Immunofluorescent Staining
Resident cardiac leukocytes (see text) were examined by two-color immunofluorescence using MKD6 mouse anti-Ia and TRITC-conjugated goat anti-mouse Ig (Sigma Chemical Co., St. Louis, MO) as a first step. The sections were then blocked with normal mouse serum before staining with various rat anti-mouse mAbs followed by FITC-mouse anti-rat Ig (Boehringer-Mannheim Biochemicals, Indianapolis, IN).

Localization of Migratory DL within Spleen. Sections of recipient spleens 2–3 d after trans-

Table 1
| Animal | Blood activity cpm/µl | Heart activity cpm | Heart weight g | Calculated blood volume µl | Blood volume/0.1 g heart µl |
|--------|-----------------------|--------------------|----------------|-----------------------------|-----------------------------|
| 1      | 101                   | 223                | 0.1086         | 2.2                         | 2.0                         |
| 2      | 134                   | 184                | 0.0874         | 1.4                         | 1.6                         |
| 3      | 100                   | 191                | 0.0995         | 1.9                         | 1.9                         |
| Mean   |                       |                    |                | 0.0965                      | 1.8                         |
plantation were first stained with TRITC-conjugated goat anti-mouse Ig and blocked with normal mouse serum before staining donor DL with B21-2 and FITC mouse anti-rat Ig.

**Immunoperoxidase Staining.** Frozen sections were stained using B21-2 anti-Ia<sup>b</sup> or 2D2C anti-Pgp-1.1 (not shown) followed by peroxidase-conjugated goat anti-rat Ig (Sigma Chemical Co.) adsorbed with normal mouse serum, after first eliminating endogenous peroxidase by incubating the sections in 10 U/ml glucose oxidase type VS (Sigma Chemical Co.) in 10 mM glucose for 30 min at 37°C. Peroxidase activity was detected using H<sub>2</sub>O<sub>2</sub>-DAB (3,3'-diaminobenzidine tetrahydrochloride; Polysciences Inc., Warrington, PA) as a chromogen. After counterstaining with Harris' hematoxylin (BDH, Ltd. Poole, UK) the slides were dehydrated and mounted in DPX (BDH, Ltd.).

**Two-color Immunogold-Peroxidase Staining.** Sections were prepared as for one-color peroxidase staining and Ia<sup>+</sup>-positive cells were stained with B21-2 and gold-conjugated goat anti-rat Ig (Janssen Life Sciences Products, Olen, Belgium) adsorbed with normal mouse serum. After blocking with 5% normal rat serum, sections were incubated with biotinylated YTS 191 (anti-CD4) or YTS 169 (anti-CD8) followed by peroxidase-conjugated goat anti-biotin (Sigma Chemical Co.). Silver enhancement (IntenSE-M; Janssen Life Sciences Products) was performed before development with DAB.

An ocular grid was used to enumerate discrete Ia<sup>+</sup>-positive cells in tissue sections of heart grafts (2 hearts/time point, 10 fields/sample). From day 3 onwards Ia<sup>+</sup> was induced on other graft elements, as noted by others (19), so DL could only be quantified in areas lacking generalized Ia expression; a similar approach has been used elsewhere (20).

Ia<sup>+</sup>-positive cells in recipient spleens were counted similarly (6-12 sections/sample) and cross-sectional areas were measured using an Optimax V image analyzer in order to standardize the number of cells per unit area. Statistical analysis was carried out using Student's t-test or χ<sup>2</sup> with Yates correction.

**Results and Discussion**

Using two-color immunofluorescent staining we identified two resident leukocyte common antigen-positive populations in mouse hearts: a strongly Ia<sup>+</sup>, Fc receptor type II<sup>+</sup> (FcRII<sup>+</sup>), phagocyte glycoprotein-1<sup>+</sup> (Pgp-1<sup>+</sup>), and complement receptor type III (CR3)-weak population of similar phenotype to LC, comprising the presumptive DL; and a smaller group which is Ia<sup>-</sup> FcRII<sup>+</sup>, Pgp-1<sup>+</sup>, and CR3-strong, perhaps comprising tissue macrophages or precursors of the Ia<sup>+</sup> population. Normal hearts contained no cells that stained for B cell markers (anti-Ig, B220, and TIB146) or T cell markers (CD4, CD5, CD8).

We wished to determine whether donor DL could migrate via the blood from vascularized organ allografts into recipients' spleens after transplantation (an efflux of these cells in the draining lymph having been reported previously [5]). BALB/c hearts (H-2d, Pgp-1.1) were transplanted into C3H/He recipients (H-2k, Pgp-1.2) and we examined the grafts for changes in density of resident DL, as well as the recipient spleens for entry of cells bearing donor alloantigens between 1-6 d later (rejection normally occurs at 8-12 d).

Over the first 4 d after transplantation there was a marked reduction in the number of Ia<sup>+</sup> DL in the graft, from a mean of 95.7 mm<sup>2</sup> (at day 0) to 9.2 mm<sup>2</sup> (Table II). At the same time that donor DL were leaving the grafts, strongly Ia<sup>b</sup>-positive cells with dendritic morphology entered the recipients' spleens (Fig. 1a and b, and Table II). These cells also labeled for the donor-strain Pgp-1 allele that is expressed by DL, further suggesting the cells were of donor origin, although we can not exclude the less likely possibility they were host-derived cells that had acquired donor alloantigens in a form recognizable by the antibodies. Donor cells were readily apparent by day 1, and maximum numbers were present between days 2 and 4 after transplantation, representing a total of ~10<sup>4</sup> cells per spleen at any given time (Table
FIGURE 1. Donor dendritic leukocytes enter recipient spleens after transplantation. Sections of C3H/He spleens from recipients of BALB/c hearts 2 d after transplantation stained to show the presence of Iaα-positive cells, note the central arteriole (a, ×250), and their dendritic morphology (b, ×1,000). Legend continued on facing page.
TABLE II

Frequencies of Donor Ia+ DL in Cardiac Allografts and Recipient Spleens

| Time after transplantation | Mean DL ± SE in cardiac allografts per mm² section | Mean donor DL ± SE in recipient spleens per 10 mm² cross-section |
|---------------------------|---------------------------------|-------------------------------------------------------------|
| 0 | 95.7 ± 8.2 | 0 |
| 1 | 47.5 ± 7.3* | 5.0 ± 0.8 |
| 2 | 17.0 ± 3.0* | 11.8 ± 1.3 |
| 3 | 9.2 ± 2.0* | 10.4 ± 0.8 |
| 4 | 28.5 ± 5.1* | 9.6 ± 1.7 |
| 6 | 1 | 0 |

Discrete Ia⁺ positive cells in tissue sections of heart grafts (2 hearts/time point, 10 fields/sample) were enumerated using an ocular grid. Ia⁺-positive cells in recipient spleens were counted similarly (6–12 sections/sample) and cross-sectional areas were measured. By multiplying the mean number of stained cells per 10-mm² section (7 μm thick) by the approximate number of sections in a spleen 1.5 cm in length (2,000), it is possible to estimate 10⁴ cells/spleen are present at any time on days 2–4.

* A significant difference compared with normal nontransplanted BALB/c hearts (day 0) (p < 0.001).

II, legend), but they were not detectable at day 6. Similar findings were made in other strain combinations (BALB/c → CBA/Ca, C57BL/10 → CBA/Ca and BALB/c → C57BL/10; data not shown).

The donor cells in the spleen were not cells such as B cells or monocytes derived from the very small amount of blood remaining in the heart graft. First, precautions were taken to avoid significant transfer of blood in the donor heart (see above). Second, experiments revealed the volume of blood transferred in a graft to be 1.8 ± 0.2 μl. (Table I). When 2.5 μl of BALB/c blood (diluted to 0.25 ml) was administered to each of three C3H/He mice, the frequency of Ia⁺-positive cells in spleen 2 d later was 0.2 ± 0.1/10 mm², indicating the donor cells in spleens of transplant recipients were not derived from blood. Hence, the donor Ia⁺ positive cells found in the recipient spleen must have come from the resident Ia⁺ leukocytes of grafted heart which we would term dendritic leukocytes, there being no resident B cells in normal cardiac tissues.

To determine where donor Ia⁺ cells were localized within the spleen, double-labeling techniques were used (Fig. 1). Donor cells were found exclusively within the peripheral white pulp that contains primarily B cells and some T cells, or at the border of this with central white pulp (dense T areas) (Fig. 1 c). On close inspection, donor cells did not appear to express surface or cytoplasmic Ig, providing fur...

Donor dendritic leukocytes localize in splenic peripheral white pulp and associate with CD4⁺ T cells. Immunofluorescence to show donor Ia⁺-positive cells (green) within the B cell rich areas (red) and at the border of B cell and T cell areas (c, ×250). Immunogold-peroxidase staining to show donor DL (black) in association with CD4⁺ T cells (brown) (d, ×250) and an Ia⁺-positive DL in a cluster of CD4⁺ T cells (e, ×400), and in contrast, donor DL not in contact with CD8⁺ T cells (f, ×400).
there evidence against their being B cells. Double staining with Ia and CD4 or CD8 mAbs revealed that 78% of donor cells were associated with CD4⁺ T cells (Fig. 1, d and e), either singly or in a cluster, but only 14% appeared to be in contact with CD8⁺ T cells (Fig. 1 f), a highly significant difference ($\chi^2 = 39, p = 0.0001$).

These findings demonstrate a novel migratory route for DL that express high levels of alloantigens and/or foreign peptide/MHC complexes from a vascularized organ allograft into the spleen (via blood, since the spleen lacks a lymphatic supply), concomitant with their disappearance from the graft. Previous investigators have noted such a reduction in both allografts and isografts, but failed to detect migration into lymphoid tissues, perhaps because endogenous peroxidase activity was not sufficiently blocked to allow detection of the relatively small numbers of cells (20). While the number of DL in the spleen at any time point is only ~10⁴ there may be a continuous flux into and out of this tissue, and a single injection of even this number of donor-strain lymphoid DC alone can precipitate allograft rejection (16, 21).

Studies have shown that depletion of DL from transplanted tissues not only has a profound influence on cellular rejection (22, 23), but also prevents the development of graft-specific antibodies (24). This is particularly interesting in light of the juxtaposition of donor DL with both T and B cells, consistent with the idea that DC play a role in the initiation of cell-mediated and T cell-dependent antibody responses in vivo, as has been shown in vitro (25). This distribution is somewhat different from that seen after intravenous administration of syngeneic splenic DC, which appear to home to the central white pulp (12). Possibly after transplantation the allogeneic DL encounter alloreactive T cells in the peripheral white pulp, soon after their migration out of the marginal zone, and their subsequent movement into the central white pulp is inhibited. Alternatively, the migratory properties of DL from nonlymphoid tissues may be distinct from those of lymphoid DC. Additional studies will be required to distinguish between these possibilities.

DL may migrate into blood in response to cytokines that are released during the inflammatory reaction that occurs after transplantation. Results of older studies favoring peripheral sensitization against fully vascularized organ allografts can now be reinterpreted as central sensitization due to migration of blood-borne DL into the spleen, and in physiological situations this most likely provides a pathway for inducing responses against antigens (e.g., viruses) derived from peripheral tissues. It is quite conceivable that DL reside in nonlymphoid organs as precursors and process antigens from the environment, before they develop into mature DC and subsequently migrate into lymphoid tissues with the ability to present these peptide/MHC complexes and activate resting T cells (9, 26). Studies to define the signals (e.g., cytokines) that regulate maturation and migration of DL from peripheral tissues may provide new strategies to overcome allograft rejection and manipulate antigen-dependent immune responses, e.g., vaccination.

Summary

It has been a long-standing dogma that host sensitization against fully-vascularized organ allografts occurs peripherally within the graft itself. In this report we show that donor-derived MHC class II-positive (Ia⁺) DL migrate rapidly out of mouse cardiac allografts into the recipients' spleens where they home to the peripheral white
pulp and associate predominantly with CD4+ T lymphocytes. This provides a novel route for central sensitization against fully vascularized allografts, and most likely represents a pathway by which immune responses are generated against antigens on blood-borne DL emigrating from peripheral tissues.

Received for publication 26 September 1989.

References

1. Austyn, J. M. 1989. Antigen-presenting cells. In In Focus Series. IRL Press, Oxford.
2. Austyn, J. M., and R. M. Steinman. 1988. The passenger leukocyte. A fresh look. Transplant. Rev. 2:139.
3. Strober, S., and J. L. Gowans. 1965. The role of lymphocytes in the sensitization of rats to renal homografts. J. Exp. Med. 122:347.
4. Hume, D. M., and R. H. Egdaal. 1955. Progressive destruction of renal homografts from regional lymphatics of the host. Surgery (St. Louis). 38:194.
5. Pedersen, N. C., and B. Morris. 1970. The role of the lymphatic system in the rejection of homografts: a study of lymph from renal transplants. J. Exp. Med. 131:936.
6. Barker, C. F., and R. E. Billingham. 1968. The role of afferent lymphatics in the rejection of skin homografts. J. Exp. Med. 128:197.
7. Tilney, N. L., and J. L. Gowans. 1970. The sensitization of rats by allografts transplanted to an alymphatic pedicle of skin. J. Exp. Med. 133:951.
8. Hall, J. G. 1967. Studies of the cells in the afferent and efferent lymph of lymph nodes draining the site of skin homografts. J. Exp. Med. 125:737.
9. Schuler, G., and R. M. Steinman. 1985. Murine epidermal Langerhans cells mature into potent immunostimulatory dendritic cells in vitro. J. Exp. Med. 161:526.
10. Kelly, R. H. 1970. Localization of afferent lymph cells within the draining node during a primary immune response. Nature (Lond.). 227:510.
11. Knight, S. C., B. M. Balfour, J. O'Brien, L. Buttifant, T. Sumerak, and J. Clarke. 1982. Role of veiled cells in lymphocyte activation. Eur. J. Immunol. 12:1067.
12. Austyn, J. M., J. W. Kupiec-Weglinski, D. F. Hankins, and P. J. Morris. 1988. Migration patterns of dendritic cells in the mouse. Homing to T cell-dependent areas of spleen, and binding with marginal zone. J. Exp. Med. 167:646.
13. Kupiec-Weglinski, J. W., J. M. Austyn, and P. J. Morris. 1988. Migration patterns of dendritic cells in the mouse. Traffic from blood, and T cell-dependent and independent entry to lymphoid tissues. J. Exp. Med. 167:632.
14. Hart, D. N. J., and J. W. Fabre. 1981. Demonstration and characterization of Ia-positive dendritic cells in the interstitial connective tissues of rat heart and other tissues, but not brain. J. Exp. Med. 153:347.
15. Corry, R. J., H. J. Winn, and P. S. Russell. 1973. Primarily vascularized allografts of hearts in mice: the role of H-2D, H-2K, and non H-2 antigens in rejection. Transplantation (Baltimore). 16:343.
16. Lechler, R. I., and J. R. Batchelor. 1982. Restoration of immunogenicity to passenger cell-depleted kidney allografts by the addition of donor strain dendritic cells. J. Exp. Med. 155:31.
17. Crowley, M., K. Inaba, M. Witmer-Pack, and R. M. Steinman. 1989. The cell surface of mouse dendritic cells: FACS analyses of dendritic cells from different tissues including thymus. Cell. Immunol. 118:108.
18. Cobbold, S. P., A. Jayasuriya, A. Nash, T. D. Prospero, and H. Waldman. 1984. Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. Nature (Lond.). 312:548.
19. Milton, A. D., and J. W. Fabre. 1985. Massive induction of donor-type class I and class II major histocompatibility complex antigens in rejecting cardiac allografts in the rat. J. Exp. Med. 161:98.

20. Forbes, R. D. C., N. A. Parfrey, M. Gomersall, A. G. Darden, and R. D. Guttman. 1986. Dendritic cell-lymphoid cell aggregation and major histocompatibility antigen expression during rat cardiac allograft rejection. J. Exp. Med. 164:1239.

21. Benson, M. T., G. Buckley, E. J. Jenkinson, and J. J. T. Owen. 1987. Survival of deoxyguanosine-treated fetal thymus allografts is prevented by priming with dendritic cells. Immunology. 60:593.

22. Faustman, D. L., R. M. Steinman, H. M. Gebel, V. Hauptfeld, J. M. Davie, and P. E. Lacy. 1984. Prevention of rejection of murine islet allografts by pretreatment with anti-dendritic cell antibody. Proc. Natl. Acad. Sci. USA. 81:3864.

23. Iwai, H., S. Kuma, M. Inaba, R. A. Good, T. Yamahita, T. Kumazawa, and S. Ikchara. 1989. Acceptance of murine thyroid allografts by pretreatment of anti-Ia antibody or anti-dendritic cell antibody in vitro. Transplantation (Baltimore). 47:45.

24. Hart, D. N. J., C. G. Winearls, and J. W. Fabre. 1980. Graft adaptation: studies on possible mechanisms in long-term surviving rat renal allografts. Transplantation (Baltimore). 30:73.

25. Inaba, K., M. Witmer, and R. M. Steinman. 1984. Clustering of dendritic cells, helper T lymphocytes, and histocompatible B cells during primary antibody responses in vitro. J. Exp. Med. 160:858.

26. Romani, N., S. Koide, M. Crowley, M. Witmer-Pack, A. M. Livingstone, C. G. Fathman, K. Inaba, and R. M. Steinman. 1989. Presentation of exogenous protein antigens by dendritic cells to T cell clones: intact protein is presented best by immature, epidermal Langerhans cells. J. Exp. Med. 169:1169.